IE
ADCT icon

Israel Englander’s ADC Therapeutics ADCT Stock Holding History

Israel Englander’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$161K Buy
150,000
+15,000
+11% +$43.8K ﹤0.01% 5378
2026
Q1 		$506K Buy
+135,000
New +$532K ﹤0.01% 4763
2024
Q3 		– Sell
-100,000
Closed -$316K – 6041
2024
Q2 		$316K Buy
+100,000
New +$397K ﹤0.01% 4881

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Israel Englander's ADCT Position: Q2 2026 in Review

Israel Englander reduced its ADC Therapeutics (ADCT) stake by 7% in Q2 2026, selling an estimated $641K and leaving 2,899,535 shares worth $3.1M. The position accounts for ﹤0.01% of the portfolio, ranked #3430.

Israel Englander first reported a position in ADCT in Q2 2020 and has held it in 21 quarters since. The position peaked at $13.1M in Q4 2022. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Israel Englander held 2,899,535 shares of ADC Therapeutics worth $3.1M as of Q2 2026.
  • Israel Englander sold 219,619 ADC Therapeutics shares in Q2 2026, an estimated $641K.
  • ADC Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3430 holding.
  • Israel Englander first reported a position in ADC Therapeutics in Q2 2020 and has held it in 21 quarters since.
  • Israel Englander's ADC Therapeutics position peaked at $13.1M in Q4 2022.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.